Logo Prima Biomed


Welcome to the Newsroom

10 August 2016

Prima BioMed receives NASDAQ Notice of Bid Price Deficiency


ENGLISH

SYDNEY, AUSTRALIA - Prima BioMed Ltd (NASDAQ: PBMD; ASX: PRR) (“Prima”, the “Company”), has received notification from the Listing Qualifications Department of The NASDAQ Stock Market (the “Staff”) indicating that, for the period from June 24, 2016 through August 5, 2016, the closing bid price of the Company’s American Depositary Shares, or ADS, had not been maintained at the minimum required closing bid price of at least US$1.00 per share as required for continued listing on The NASDAQ Global Market pursuant to NASDAQ Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).

(...)